2Ismail IS, Scanlon MF, Peters JR. Cholinergic control of growth hormone(GH) response to GH-releasing hormone in insulin-dependent diabetics. Evedence for attenuated hypothalamic somatostatinergic tone and decreased GH autofeedbaek [ J ]. Clin Endocrinol ( Oxf), 1993,38 ( 2 ) :149-157.
3Fujihara M, Uemasu J, Kawasaki H. Serum and urinary levels of insulin-like growth factor I in patients with chronic renal disease and diabetes mellitus:its clinic implication[J] .Clin Nephrol, 1996,45(6):372-378.
4Matina V, Bruno G, Taglibbue M, et al. Blunted GH response to growth hormone-releasing hormone (GHRH) alone or combined with arginine in non-insulin-dependent diabetes mellitus[ J ]. Horm Metab Res, 1995,27(1) :26-30.
5Bach LA, Rechler MM. Insulin-like growth factors and diabetes[ J]. Diabetes Metab Rev, 1992,8(3):229-257.
6Rechler MM, Clemmons D. Growth inhibition by insulin-like growth factor (IGF) binding protein-3-what's IGF got to do with it[ J] ? Endocrinology, 1997,138(7 ) : 2645-2647.
7Flyvbjerg A, Jorgensen KD, Marshall SM, et al. Inhibitory effect of octreotide on growth hormone-induced IGF- I generation and organ growth in hypophysectomized rats [ J]. Am J Physiol, 1991,260 (4 Pt 1 ) :E568-574.
8Merimee TJ. Diabetic retinopathy : A synthesis of perspectives [ J ]. N Engl J Med, 1990,322(14) :978-983.
9Sonksen PH, Russell-Jones D, Jones RH. Growth hormone and diabetes mellitus: a review of sixty-three years of medical research and aglimpse into the future[J]? Horm Res, 1993,40(1-3):68-79.
10Merimee T. The interface between diabetic retinopathy, diabetes management, and insulin-like growth factors ( Editorial ) [ J ]. J Clin Endocrinol Metab, 1997,82(9) :2806-2808.
3Gavrilova NA, Lanevskaia NI, Antsiferova NG. A marker of early stage of diabetic retinopathy[J]. Izv Akad Nauk Ser Biol, 2002, 11 (6): 705-709.
4Fernyhough P, Huang TJ, Verkhratsky A. Mechanism of microchondrial dysfunctionin diabetic sensory neuropathy [J]. Peripher Nerv Syst, 2003, 8 (4): 227-235.
5Buckmaster PS, Otero-Corehan V, Rubinstein M, et al. Heightened seizure severity in somatostatin knockout mice [J]. EpilepsyRes, 2002, 48 (1): 43-56.
6Nilsson CL, Brinkmalm A, Minthon L, et al. Processing of neuropeptide Y, galanin and somatostatin in the cerebrospinal fluid of patients with Alzheimer' s disease and frontotemporal dementia[J]. Peptides, 2001, 22 (12): 2105-2112.
7Grant MB, Mames RN, Fitzgerald C, et al. The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy [J]. Diabetes Care, 2000, 23 (4): 504-509.
8Hyer SL, Sharp PS, Rrooks RA, et al. Continuous subcutaneous octreotide infusion markedly suppresses IGF-1 levels whilst only partially suppressing GH secretion in diabetics with retinopathy [J]. Acta Endocrinol Copenh, 1989, 120 (2): 187-194.
9Li Q, Zemel E, Miller B, et al. Early retinal damage in experimental diabetes : electroretinographical and morphological observations [ J]. Exp Eye Res, 2002,74 (5): 615-625.
10Kiszkielis M, Lubiflski W, Penkala K. The photopic negative response as a promising diagnostic tool in glaucoma. A review[J]. Klin Oczna, 2012, 114 (2): 138-142.
